STOCK TITAN

Exelixis (EXEL) director nets 30,250-share sale and option exercise

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Exelixis, Inc. director Bob Oliver reported mixed activity in company stock. On February 13, 2026, he sold 9,088 shares of common stock in an open-market transaction at $43.61 per share and separately sold 21,162 shares at a weighted average price of $43.90 per share, with individual trades between $43.90 and $43.96 as noted in a footnote.

On the same date, he exercised an option for 9,088 shares of common stock, recorded as both a derivative exercise and an acquisition of common shares at an exercise price of $19.28 per share. A footnote states this option originally covered 36,353 shares and became fully exercisable on May 31, 2023. Another footnote notes 18,900 restricted stock units that will convert into common shares upon vesting.

Positive

  • None.

Negative

  • None.
Insider Oliver Bob
Role Director
Sold 30,250 shs ($1.33M)
Type Security Shares Price Value
Exercise Option (right to buy) 9,088 $0.00 --
Exercise Common Stock 9,088 $19.28 $175K
Sale Common Stock 9,088 $43.61 $396K
Sale Common Stock 21,162 $43.90 $929K
Holdings After Transaction: Option (right to buy) — 12,118 shares (Direct); Common Stock — 51,370 shares (Direct)
Footnotes (1)
  1. Includes 18,900 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $43.90 to $43.96. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. The option, representing the right to purchase a total of 36,353 shares of Common Stock, became fully exercisable on May 31, 2023.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Oliver Bob

(Last) (First) (Middle)
C/O EXELIXIS, INC.
1851 HARBOR BAY PARKWAY

(Street)
ALAMEDA CA 94502

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
EXELIXIS, INC. [ EXEL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/13/2026 M 9,088 A $19.28 51,370(1) D
Common Stock 02/13/2026 S 9,088 D $43.61 42,282(1) D
Common Stock 02/13/2026 S 21,162 D $43.9(2) 21,120(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option (right to buy) $19.28 02/13/2026 M 9,088 05/31/2023(3) 05/30/2030 Common Stock 9,088 $0 12,118 D
Explanation of Responses:
1. Includes 18,900 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.
2. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $43.90 to $43.96. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
3. The option, representing the right to purchase a total of 36,353 shares of Common Stock, became fully exercisable on May 31, 2023.
Remarks:
/s/ Nina Ayer, Attorney in Fact 02/18/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Exelixis (EXEL) director Bob Oliver do in this Form 4?

Bob Oliver reported both sales and an option exercise in Exelixis common stock. He sold shares in two open-market transactions and exercised a stock option that delivered additional common shares on the same date.

How many Exelixis (EXEL) shares did Bob Oliver sell and at what prices?

He sold 9,088 Exelixis common shares at $43.61 per share and 21,162 shares at a weighted average price of $43.90, with individual trades between $43.90 and $43.96, as described in the filing footnote.

What option did Bob Oliver exercise in Exelixis (EXEL) stock?

He exercised an option covering 9,088 shares of Exelixis common stock at an exercise price of $19.28 per share. A footnote explains this option originally represented the right to purchase 36,353 shares and became fully exercisable on May 31, 2023.

Is Bob Oliver’s Exelixis (EXEL) transaction an open-market sale?

Yes. The Form 4 describes two transactions coded “S” as sales of Exelixis common stock in the open market. One block was sold at $43.61, and another at a weighted average price of $43.90 per share, within a narrow price range.

Does Bob Oliver have additional Exelixis (EXEL) equity through restricted stock units?

Yes. A footnote states 18,900 shares of Exelixis common stock will be issued to him upon vesting of restricted stock units. Each restricted stock unit represents the economic equivalent of one share of common stock when it converts.

What does the Form 4 say about the exercisability of Bob Oliver’s Exelixis option?

The filing notes that the option, covering 36,353 Exelixis common shares, became fully exercisable on May 31, 2023. The reported February 13, 2026 transaction reflects the exercise of 9,088 of those option shares into common stock.